APT: Continuing Dual Antiplatelet Therapy (DAPT) Post-PCI

Antiplatelet therapy (APT) has become an important tool in the treatment and prevention of atherosclerotic events, particularly those associated with coronary artery disease. A large evidence base has evolved regarding the relationship between antiplatelet therapy prescription in various clinical contexts and risk/benefit relationships.
Coronary revascularization procedures such as percutaneous coronary intervention or “PCI” are a mainstay of management of patients with coronary artery disease.
This video presents the Canadian Cardiovascular Society’s Antiplatelet Therapy Guideline recommendations for the duration of DAPT in patients who undergo PCI in ACS (2:14) and non-ACS (6:25) settings.

[@RadioReprised]

Thanks for that straight forward report.......now I understand why I will be on dapt for the rest of my life. Too many stents and too many risk factors . .